215 related articles for article (PubMed ID: 36788066)
1. Digital Image Analysis of Ki67 Heterogeneity Improves the Diagnosis and Prognosis of Gastroenteropancreatic Neuroendocrine Neoplasms.
Zhang M; Tan C; Wang X; Ding X; Zhang B; Yang Z; Wang Y; Sheng W; Huang D
Mod Pathol; 2023 Jan; 36(1):100017. PubMed ID: 36788066
[TBL] [Abstract][Full Text] [Related]
2. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms.
Klöppel G; La Rosa S
Virchows Arch; 2018 Mar; 472(3):341-349. PubMed ID: 29134440
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
4. Digital Image Analysis of the Proliferation Markers Ki67 and Phosphohistone H3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Accuracy of Grading Compared With Routine Manual Hot Spot Evaluation of the Ki67 Index.
Lea D; Gudlaugsson EG; Skaland I; Lillesand M; Søreide K; Søreide JA
Appl Immunohistochem Mol Morphol; 2021 Aug; 29(7):499-505. PubMed ID: 33758143
[TBL] [Abstract][Full Text] [Related]
5. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
[TBL] [Abstract][Full Text] [Related]
6. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification.
Yang Z; Tang LH; Klimstra DS
Am J Surg Pathol; 2011 Jun; 35(6):853-60. PubMed ID: 21566513
[TBL] [Abstract][Full Text] [Related]
7. Clinico-morphological analysis of the neuroendocrine neoplasms of the gastroenteropancreatic system.
Delektorskaya VV; Kozlov NA; Chemeris GY
Klin Lab Diagn; 2013 Oct; (10):48-50, 10-3. PubMed ID: 24640093
[TBL] [Abstract][Full Text] [Related]
8. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
Yin F; Wu ZH; Lai JP
World J Gastroenterol; 2022 May; 28(17):1751-1767. PubMed ID: 35633912
[TBL] [Abstract][Full Text] [Related]
9. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
[TBL] [Abstract][Full Text] [Related]
10. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods.
Tang LH; Gonen M; Hedvat C; Modlin IM; Klimstra DS
Am J Surg Pathol; 2012 Dec; 36(12):1761-70. PubMed ID: 23026928
[TBL] [Abstract][Full Text] [Related]
11. Ki-67 Proliferation Index Assessment in Gastroenteropancreatic Neuroendocrine Tumors by Digital Image Analysis With Stringent Case and Hotspot Level Concordance Requirements.
Boukhar SA; Gosse MD; Bellizzi AM; Rajan K D A
Am J Clin Pathol; 2021 Sep; 156(4):607-619. PubMed ID: 33847759
[TBL] [Abstract][Full Text] [Related]
12. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
Shi H; Zhang Q; Han C; Zhen D; Lin R
BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
[TBL] [Abstract][Full Text] [Related]
13. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
[TBL] [Abstract][Full Text] [Related]
14. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
[TBL] [Abstract][Full Text] [Related]
15. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
Janson ET; Sorbye H; Welin S; Federspiel B; Grønbæk H; Hellman P; Ladekarl M; Langer SW; Mortensen J; Schalin-Jäntti C; Sundin A; Sundlöv A; Thiis-Evensen E; Knigge U
Acta Oncol; 2014 Oct; 53(10):1284-97. PubMed ID: 25140861
[TBL] [Abstract][Full Text] [Related]
16. Potential Pitfalls in Diagnostic Digital Image Analysis: Experience with Ki-67 and PHH3 in Gastrointestinal Neuroendocrine Tumors.
Hacking SM; Sajjan S; Lee L; Ziemba Y; Angert M; Yang Y; Jin C; Chavarria H; Kataria N; Jain S; Nasim M
Pathol Res Pract; 2020 Mar; 216(3):152753. PubMed ID: 31761497
[TBL] [Abstract][Full Text] [Related]
17. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
[TBL] [Abstract][Full Text] [Related]
18. CD44v6 expression in gastroenteropancreatic neuroendocrine neoplasms: Clinicopathological correlation and prognosis.
Nibhondhratana P; Watcharadetwittaya S; Sa-Ngiamwibool P
Pathol Res Pract; 2022 Dec; 240():154213. PubMed ID: 36403312
[TBL] [Abstract][Full Text] [Related]
19. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time.
Wang SJ; Whitman J; Paciorek A; Le BK; Nakakura EK; Behr SC; Joseph N; Zhang L; Hope TA; Bergsland EK
J Neuroendocrinol; 2023 Apr; 35(4):e13260. PubMed ID: 37002881
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): what's better?
Milione M
Endocrine; 2018 Jan; 59(1):1-3. PubMed ID: 28417314
[No Abstract] [Full Text] [Related]
[Next] [New Search]
